Clicky

News Feeds

HealthFolk's News section is a health news aggregator with a focus on Nigeria, and Africa as a whole.

[Seminar] Hepatitis C

Tags: General

  • 1.

    Global hepatitis report 2017.

    World Health Organization, Geneva
  • 2.
    • Polaris Observatory HCV Collaborators

    Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

    Lancet Gastroenterol Hepatol. 2: 161-176
  • 3.

    Global health sector strategy on viral hepatitis 2016–2021.

    World Health Organization, Geneva
  • 4.
    • Platt L
    • Easterbrook P
    • Gower E
    • et al.

    Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

    Lancet Infect Dis. 16: 797-808
  • 5.
    • Borgia SM
    • Hedskog C
    • Parhy B
    • et al.

    Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes.

    J Infect Dis. 218: 1722-1729
  • 6.
    • Messina JP
    • Humphreys I
    • Flaxman A
    • et al.

    Global distribution and prevalence of hepatitis C virus genotypes.

    Hepatology. 61: 77-87
  • 7.

    Pangenotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions.

    J Viral Hepat. 24: 92-101
  • 8.
    • Cooke GS
    • Andrieux-Meyer I
    • Applegate TL
    • et al.

    Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

    Lancet Gastroenterol Hepatol. 4: 135-184
  • 9.
    • Lanini S
    • Easterbrook PJ
    • Zumla A
    • Ippolito G

    Hepatitis C: global epidemiology and strategies for control.

    Clin Microbiol Infect. 22: 833-838
  • 10.
    • Kouyoumjian SP
    • Chemaitelly H
    • Abu-Raddad LJ

    Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions.

    Sci Rep. 81661
  • 11.
    • Mahajan R
    • Midha V
    • Goyal O
    • et al.

    Clinical profile of hepatitis C virus infection in a developing country: India.

    J Gastroenterol Hepatol. 33: 926-933
  • 12.
    • Botheju WSP
    • Zghyer F
    • Mahmud S
    • Terlikbayeva A
    • El-Bassel N
    • Abu-Raddad LJ

    The epidemiology of hepatitis C virus in Central Asia: systematic review, meta-analyses, and meta-regression analyses.

    Sci Rep. 92090
  • 13.
    • Pepin J
    • Abou Chakra CN
    • Pepin E
    • Nault V
    • Valiquette L

    Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010.

    PLoS One. 9e99677
  • 14.
    • Degenhardt L
    • Peacock A
    • Colledge S
    • et al.

    Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

    Lancet Glob Health. 5: e1192-e1207
  • 15.
    • Lim AG
    • Qureshi H
    • Mahmood H
    • et al.

    Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.

    Int J Epidemiol. 47: 550-560
  • 16.
    • Tsertsvadze T
    • Sharvadze L
    • Chkhartishvili N
    • et al.

    The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.

    Virol J. 13: 22
  • 17.
    • Solomon SS
    • Mehta SH
    • Srikrishnan AK
    • et al.

    Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.

    Lancet Infect Dis. 15: 36-45
  • 18.
    • Jordan AE
    • Perlman DC
    • Neurer J
    • Smith DJ
    • Des Jarlais DC
    • Hagan H

    Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis.

    Int J STD AIDS. 28: 145-159
  • 19.
    • Jin F
    • Matthews GV
    • Grulich AE

    Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.

    Sex Health. 14: 28-41
  • 20.
    • Daskalopoulou M
    • Rodger A
    • Thornton A
    • et al.

    Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study.

    J Int AIDS Soc. 1719630
  • 21.
    • Hoornenborg E
    • Achterbergh RCA
    • Schim van der Loeff MF
    • et al.

    MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.

    AIDS. 31: 1603-1610
  • 22.
    • Terrault NA
    • Dodge JL
    • Murphy EL
    • et al.

    Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study.

    Hepatology. 57: 881-889
  • 23.
    • Benova L
    • Mohamoud YA
    • Calvert C
    • Abu-Raddad LJ

    Vertical transmission of hepatitis C virus: systematic review and meta-analysis.

    Clin Infect Dis. 59: 765-773
  • 24.
    • Sonderup MW
    • Afihene M
    • Ally R
    • et al.

    Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.

    Lancet Gastroenterol Hepatol. 2: 910-919
  • 25.
    • Moazen B
    • Saeedi Moghaddam S
    • Silbernagl MA
    • et al.

    Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates.

    Epidemiol Rev. 40: 58-69
  • 26.
    • Heffernan A
    • Cooke GS
    • Nayagam S
    • Thursz M
    • Hallett TB

    Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.

    Lancet. 393: 1319-1329
  • 27.
    • Platt L
    • Minozzi S
    • Reed J
    • et al.

    Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

    Addiction. 113: 545-563
  • 28.

    Global state of harm reduction 2018.

    Harm Reduction International, London
  • 29.
    • O'Keefe D
    • Stoové M
    • Doyle J
    • Dietze P
    • Hellard M

    Injecting drug use in low and middle-income countries: opportunities to improve care and prevent harm.

    J Viral Hepat. 24: 714-724
  • 30.

    Prison-based needle and syringe programmes (PNSP)—still highly controversial after all these years.

    Drugs (Abingdon Engl). 23: 103-112
  • 31.
    • Larney S
    • Kopinski H
    • Beckwith CG
    • et al.

    Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis.

    Hepatology. 58: 1215-1224
  • 32.
    • Salazar-Vizcaya L
    • Kouyos RD
    • Zahnd C
    • et al.

    Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions.

    Hepatology. 64: 1856-1869
  • 33.
    • Hajarizadeh B
    • Grebely J
    • Martinello M
    • Matthews GV
    • Lloyd AR
    • Dore GJ

    Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

    Lancet Gastroenterol Hepatol. 1: 317-327
  • 34.
    • Olafsson S
    • Tyrfingsson T
    • Runarsdottir V
    • et al.

    Treatment as prevention for hepatitis C (TraP Hep C)—a nationwide elimination programme in Iceland using direct-acting antiviral agents.

    J Intern Med. 283: 500-507
  • 35.
    • Palmateer NE
    • Taylor A
    • Goldberg DJ
    • et al.

    Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.

    PLoS One. 9e104515
  • 36.
    • Martins J
    • Rodrigues J
    • Martins AP
    • et al.

    Long-term effect of the Portuguese universal access program to new generation direct-acting antivirals for the treatment of hepatitis C.

    J Hepatol. 64: S778-S779
  • 37.

    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: a case for treatment as prevention.

    J Viral Hepat. 24: 486-495
  • 38.
    • Zelenev A
    • Li J
    • Mazhnaya A
    • Basu S
    • Altice FL

    Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.

    Lancet Infect Dis. 18: 215-224
  • 39.
    • Metzig C
    • Surey J
    • Francis M
    • Conneely J
    • Abubakar I
    • White PJ

    Impact of Hepatitis C treatment as prevention for people who inject drugs is sensitive to contact network structure.

    Sci Rep. 71833
  • 40.
    • Dore GJ
    • Bartlett SR
    • Fox P
    • et al.

    Demonstration of near-elimination of hepatitis C virus among a prison population: the lotus glen correctional centre hepatitis C treatment project.

    Clin Infect Dis. 67: 460-463
  • 41.
    • Pedrana A
    • Howell J
    • Schroeder S
    • et al.

    Eliminating viral hepatitis: the investment case.

    World Innovation Summit for Health, Doha, Qatar
  • 42.
    • Hellard M
    • McBryde E
    • Sacks Davis R
    • et al.

    Hepatitis C transmission and treatment as prevention—the role of the injecting network.

    Int J Drug Policy. 26: 958-962
  • 43.
    • Scott N
    • McBryde ES
    • Thompson A
    • Doyle JS
    • Hellard ME

    Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.

    Gut. 66: 1507-1515
  • 44.
    • Rossi C
    • Butt ZA
    • Wong S
    • et al.

    Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.

    J Hepatol. 69: 1007-1014
  • 45.

    Natural history of hepatitis C.

    Gastroenterology Clinics of North America. 44: 717-734
  • 46.
    • Beinhardt S
    • Payer BA
    • Datz C
    • et al.

    A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.

    J Hepatol. 59: 972-977
  • 47.
    • Bethea ED
    • Chen Q
    • Hur C
    • Chung RT
    • Chhatwal J

    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.

    Hepatology. 67: 837-846
  • 48.
    • Deterding K
    • Spinner CD
    • Schott E
    • et al.

    Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

    Lancet Infect Dis. 17: 215-222
  • 49.
    • Rockstroh JK
    • Bhagani S
    • Hyland RH
    • et al.

    Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.

    Lancet Gastroenterol Hepatol. 2: 347-353
  • 50.
    • Ovrehus ALH
    • Krarup H
    • Birkemose I
    • et al.

    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.

    J Hepatol. 68: 840-842
  • 51.

    EASL recommendations on treatment of hepatitis C 2018.

    J Hepatol. 69: 461-511
  • 52.
    • Thein HH
    • Yi Q
    • Dore GJ
    • Krahn MD

    Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.

    Hepatology. 48: 418-431
  • 53.
    • Bruden DJT
    • McMahon BJ
    • Townshend-Bulson L
    • et al.

    Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska cohort.

    Hepatology. 66: 37-45
  • 54.
    • Negro F
    • Forton D
    • Craxi A
    • Sulkowski MS
    • Feld JJ
    • Manns MP

    Extrahepatic morbidity and mortality of chronic hepatitis C.

    Gastroenterology. 149: 1345-1360
  • 55.
    • Hutin YJ
    • Bulterys M
    • Hirnschall GO

    How far are we from viral hepatitis elimination service coverage targets?.

    J Int AIDS Soc. 21e25050
  • 56.

    Guidelines on hepatitis B and C testing.

    World Health Organization, Geneva
  • 57.

    A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C.

    Ann Intern Med. 166: 895-896
  • 58.
    • Alfaleh FZ
    • Nugrahini N
    • Matičič M
    • et al.

    Strategies to manage hepatitis C infection disease burden - volume 3.

    J Viral Hepat. 22: 42-65
  • 59.
    • Zibbell HE
    • Asher AK
    • Patel RC
    • et al.

    Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014.

    Am J Public Health. 108: 175-181
  • 60.
    • Marot A
    • Belaid A
    • Orlent H
    • et al.

    Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a western European country: comparison with monoinfected patients.

    Clin Res Hepatol Gastroenterol. 41: 656-663
  • 61.
    • Cortesi PA
    • Barca R
    • Giudicatti G
    • et al.

    Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.

    Aliment Pharmacol Ther. 49: 1126-1133
  • 62.

    Universal screening for hepatitis C: an important step in virus elimination.

    Clin Gastroenterol Hepatol. 17: 835-837
  • 63.
    • Chevaliez S
    • Feld J
    • Cheng K
    • et al.

    Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen.

    Antivir Ther. 23: 211-217
  • 64.
    • Freiman JM
    • Wang J
    • Easterbrook PJ
    • et al.

    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.

    J Hepatol. 71: 62-70
  • 65.
    • Lange B
    • Roberts T
    • Cohn J
    • et al.

    Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples—a systematic review and meta-analysis.

    BMC Infect Dis. 17: 693
  • 66.
    • Parr JB
    • Lodge EK
    • Holzmayer V
    • et al.

    An efficient, large-scale survey of hepatitis C viremia in the Democratic Republic of the Congo using dried blood spots.

    Clin Infect Dis. 66: 254-260
  • 67.
    • Yoshida EM
    • Sulkowski MS
    • Gane EJ
    • et al.

    Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.

    Hepatology. 61: 41-45
  • 68.
    • Carrat F
    • Fontaine H
    • Dorival C
    • et al.

    Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

    Lancet. 393: 1453-1464
  • 69.
    • Younossi ZM
    • Stepanova M
    • Asselah T
    • et al.

    Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes.

    Clin Infect Dis. 66: 1742-1750
  • 70.
    • The French METAVIR Cooperative Study Group

    Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.

    Hepatology. 20: 15-20
  • 71.

    Management of the patient with SVR.

    J Hepatol. 65: S120-S209
  • 72.
    • AASLD-IDSA HCV Guidance Panel

    Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.

    Clin Infect Dis. 67: 1477-1492
  • 73.
    • Lim JK
    • Flamm SL
    • Singh S
    • Falck-Ytter YT

    American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis.

    Gastroenterology. 152: 1536-1543
  • 74.
    • European Association for the Study of Liver

    EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.

    J Hepatol. 63: 237-264
  • 75.
    • Leroy V
    • Sturm N
    • Faure P
    • et al.

    Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    J Hepatol. 61: 28-34
  • 76.
    • Yen Y-H
    • Kuo F-Y
    • Kee K-M
    • et al.

    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.

    PLoS One. 13e0199760
  • 77.

    Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries.

    World Health Organization, Geneva
  • 78.

    Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.

    World Health Organization, Geneva
  • 79.

    Hepatitis C Virus Resistance to direct-acting antiviral drugs in interferon-free regimens.

    Gastroenterology. 151: 70-86
  • 80.
    • Geddawy A
    • Ibrahim YF
    • Elbahie NM
    • Ibrahim MA

    Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction.

    Journal Transl Int Med. 5: 8-17
  • 81.
    • Hill A
    • Tahat L
    • Mohammed MK
    • et al.

    Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals.

    J Virus Erad. 4: 128-131
  • 82.
    • Gupta S
    • Rout G
    • Patel AH
    • et al.

    Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.

    J Viral Hepat. 25: 771-778
  • 83.
    • Tsai N
    • Bacon B
    • Curry M
    • et al.

    SAT-244—Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network.

    J Hepatol. 66: S726
  • 84.

    Landis CS, Sulkowski MS, Reau N, et al. Safety and efficacy of velpatasvir and sofosbuvir-based regimens for the treatment of HCV genotype 1–6: results of the HCV-TARGET study. The Liver Meeting; Washington, DC; Oct 20–24, 2017. 587.

  • 85.
    • Wyles D
    • Brau N
    • Kottilil S
    • et al.

    Sofosbuvir and velpatasvir for the treatment of hepatitis C Virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 Study.

    Clin Infect Dis. 65: 6-12
  • 86.
    • Feld JJ
    • Jacobson IM
    • Hezode C
    • et al.

    Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.

    N Engl J Med. 373: 2599-2607
  • 87.
    • Asselah T
    • Bourgeois S
    • Pianko S
    • et al.

    Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1–6 and compensated cirrhosis or advanced fibrosis.

    Liver Int. 38: 443-450
  • 88.
    • Foster GR
    • Afdhal N
    • Roberts SK
    • et al.

    Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.

    N Engl J Med. 373: 2608-2617
  • 89.
    • Esteban R
    • Pineda JA
    • Calleja JL
    • et al.

    Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis.

    Gastroenterology. 155: 1120-1127
  • 90.
    • Afdhal N
    • Reddy KR
    • Nelson DR
    • et al.

    Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

    N Engl J Med. 370: 1483-1493
  • 91.
    • Kowdley KV
    • Gordon SC
    • Reddy KR
    • et al.

    Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

    N Engl J Med. 370: 1879-1888
  • 92.
    • Vermehren J
    • Maasoumy B
    • Maan R
    • et al.

    Applicability of hepatitis C virus RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C virus genotype 1 infection.

    Clin Infect Dis. 62: 1228-1234
  • 93.
    • Kowdley KV
    • Sundaram V
    • Jeon CY
    • et al.

    Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

    Hepatology. 65: 1094-1103
  • 94.
    • Naggie S
    • Cooper C
    • Saag M
    • et al.

    Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.

    N Engl J Med. 373: 705-713
  • 95.
    • Kohli A
    • Kapoor R
    • Sims Z
    • et al.

    Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

    Lancet Infect Dis. 15: 1049-1054
  • 96.
    • Abergel A
    • Asselah T
    • Metivier S
    • et al.

    Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.

    Lancet Infect Dis. 16: 459-464
  • 97.
    • Gane EJ
    • Hyland RH
    • An D
    • et al.

    Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.

    Gastroenterology. 149: 1454-1461
  • 98.
    • Wong KA
    • Worth A
    • Martin R
    • et al.

    Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

    Antimicrob Agents Chemother. 57: 6333-6340
  • 99.
    • Gupta N
    • Mbituyumuremyi A
    • Kabahizi J
    • et al.

    Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

    Lancet Gastroenterol Hepatol. 4: 119-126
  • 100.
    • Fourati S
    • Rodriguez C
    • Hezode C
    • et al.

    Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.

    Hepatology. 69: 513-523
  • 101.

    Direct-acting antiviral therapy in sub-Saharan Africa.

    Lancet Gastroenterol Hepatol. 4: 85-86
  • 102.
    • Childs K
    • Davis C
    • Cannon M
    • et al.

    Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C.

    J Hepatol. ()
  • 103.
    • Sulkowski MS
    • Gardiner DF
    • Rodriguez-Torres M
    • et al.

    Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

    N Engl J Med. 370: 211-221
  • 104.
    • Luetkemeyer AF
    • McDonald C
    • Ramgopal M
    • Noviello S
    • Bhore R
    • Ackerman P

    12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens.

    Clin Infect Dis. 62: 1489-1496
  • 105.
    • Poordad F
    • Schiff ER
    • Vierling JM
    • et al.

    Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

    Hepatology. 63: 1493-1505
  • 106.
    • Belperio PS
    • Shahoumian TA
    • Loomis TP
    • Mole LA
    • Backus LI

    Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.

    J Hepatol. 70: 15-23
  • 107.

    Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.

    World Health Organization, Geneva
  • 108.
    • Iwamoto M
    • Sonderup MW
    • Sann K
    • et al.

    Real-world effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin among genotype 5 and 6 hepatitis C virus patients.

    Hepatology. 66 : 1264A-1265A
  • 109.
    • Omar H
    • El Akel W
    • Elbaz T
    • et al.

    Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.

    Aliment Pharmacol Ther. 47: 421-431
  • 110.
    • Kwo PY
    • Poordad F
    • Asatryan A
    • et al.

    Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis.

    J Hepatol. 67: 263-271
  • 111.

    Brown RS Jr, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the Expedition-8 study. The Liver Meeting; San Francisco, CA; Nov 9–13, 2018.

  • 112.
    • Berg T
    • Naumann U
    • Stoehr A
    • et al.

    Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.

    Aliment Pharmacol Ther. 49: 1052-1059
  • 113.
    • Zeuzem S
    • Foster GR
    • Wang S
    • et al.

    Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection.

    N Engl J Med. 378: 354-369
  • 114.
    • Krishnan P
    • Pilot-Matias T
    • Schnell G
    • et al.

    Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials.

    Antimicrob Agents Chemother. 62: e01249-e01318
  • 115.
    • Zeuzem S
    • Ghalib R
    • Reddy KR
    • et al.

    Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial.

    Ann Intern Med. 163: 1-13
  • 116.
    • Zeuzem S
    • Serfaty L
    • Vierling J
    • et al.

    The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

    J Gastroenterol. 53: 679-688
  • 117.

    Abergel A, Loustaud-Ratti V, Di Martino V, et al. High efficacy and safety of the combination HCV regimen grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study. The International Liver Congress; Paris, France; April 11–15, 2018.

  • 118.
    • Kwo P
    • Gane EJ
    • Peng CY
    • et al.

    Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection.

    Gastroenterology. 152: 164-175
  • 119.
  • Read more at the original link...

    0 comments
    Report            

    Read On:

    Are you a doctor? Click here and signup to join medical discussion forums, and receive medical job alerts! Free!

    Medical Jobs

    Tags

      
      
     

    Most Recent

    Doctor? Click here to signup to receive news & research in your specialty